# Triumvira Immunologics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/triumvira-immunologics

- Industry: Biotechnology
- Headquarters: Austin, US
- Website: www.triumvira.com
- Total disclosed funding: $64M
- Latest round: Series A (Mar 17, 2022)
- Investors on record: 9

## About

Triumvira Immunologics, Inc. focuses on developing advanced immunotherapy treatments using its proprietary T cell Antigen Coupler (TAC) technology to enhance immune responses against cancer.Founded in 2015 in Austin, US, Triumvira Immunologics specializes in immunotherapy solutions. The company recently raised USD 9.01 million in Series A funding on March 17, 2022, led by B Capital Group, with participation from other investors including ATEM Capital and Myeloma Investment Fund. The CEO is Paul Lammers, while Jonathan Bramson is the founder.Triumvira Immunologics specializes in advanced immunotherapy solutions utilizing their proprietary T cell Antigen Coupler (TAC) technology. This innovative platform enhances the immune response by enabling T cells to recognize and target a variety of cancer antigens, thereby facilitating the destruction of both liquid and solid tumors. The TAC technology operates through natural T cell activation and signaling mechanisms, resulting in controlled and effective anti-tumor responses. Triumvira is currently developing multiple TAC-based therapeutic candidates, including TAC101-CLDN18.2, which specifically targets Claudin 18.2 in advanced solid tumors. The primary end users of these therapies encompass patients with difficult-to-treat cancers, and the geographical markets for these products include North America and Europe, where the demand for novel cancer treatments is significant.Triumvira Immunologics generates revenue through partnerships and collaborations with healthcare providers, research institutions, and pharmaceutical firms focused on oncology. The company's transaction structure is primarily based on B2B arrangements, where therapeutic candidates are developed and tested in clinical trials, potentially leading to commercialization upon successful outcomes. Revenue streams may arise from licensing agreements, where Triumvira licenses its proprietary TAC technology to partners for further development and marketing. The flagship product, TAC101-CLDN18.2, represents a significant aspect of the company's offerings, with its development geared towards addressing the unmet needs of patients with solid tumors. Financial transactions typically involve milestone payments tied to specific clinical trial achievements, as well as royalties from product sales once market approval is obtained.Triumvira Immunologics plans to utilize the recent Series A funding of USD 9.01 million raised in March 2022 to advance the development of new products, including further enhancements to their TAC-based therapies. The company is focused on expanding its market presence in North America and Europe, aiming to meet the growing demand for innovative cancer therapies. This funding will support clinical trials and potential commercialization of TAC101-CLDN18.2 and other candidates, reinforcing Triumvira's commitment to addressing significant unmet medical needs in oncology.

## Funding rounds

- Series A, Mar 17, 2022, $9M — ATEM Capital, B Capital, Northpond Ventures, Leaps by Bayer, Myeloma Investment Fund
- Series A, Aug 27, 2020, $55M — C3I Capital Management, Bloom Burton & Co., Oceanpine Capital, Northpond Ventures, Viva Biotech Holdings, Leaps by Bayer

## Investors

- C3I Capital Management — Series A
- Bloom Burton & Co. — Series A
- Oceanpine Capital (https://capitalatlas.ai/funds/oceanpine-capital) — Series A
- Northpond Ventures (https://capitalatlas.ai/funds/northpond-ventures) — Series A
- Viva Biotech Holdings — Series A
- Leaps by Bayer (https://capitalatlas.ai/funds/leaps-by-bayer) — Series A
- ATEM Capital (https://capitalatlas.ai/funds/atem-capital) — Series A
- B Capital (https://capitalatlas.ai/funds/b-capital) — Series A
- Myeloma Investment Fund (https://capitalatlas.ai/funds/myeloma-investment-fund) — Series A